The fastest-growing and largest of the 20 sized Pharmaceuticals markets in China, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $3 Bn | $30.9 Bn | 26.4% | 34 |
| 2 | Cell Based Immunotherapy | $1.3 Bn | $11.9 Bn | 24.5% | 5,435 |
| 3 | Cannabidiol (CBD) | $1.8 Bn | $9.5 Bn | 18.3% | 9 |
| 4 | Cannabis | $2.7 Bn | $11 Bn | 15% | 5 |
| 5 | Atopic Dermatitis Drugs | $903 Mn | $3.3 Bn | 13.7% | 73 |
| 6 | Oncology/Cancer Drugs | $14.2 Bn | $36.6 Bn | 9.9% | 7,323 |
| 7 | Anti-Aging | $7.1 Bn | $17.7 Bn | 9.6% | 146 |
| 8 | Diabetes Management | $6.3 Bn | $14.3 Bn | 8.6% | 399 |
| 9 | Alzheimer Drugs | $403 Mn | $894 Mn | 8.3% | 148 |
| 10 | Contraceptives Drugs | $2 Bn | $4.5 Bn | 8.3% | 0 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $14.2 Bn | $36.6 Bn | 9.9% | 7,323 |
| 2 | Anti-Aging | $7.1 Bn | $17.7 Bn | 9.6% | 146 |
| 3 | Diabetes Management | $6.3 Bn | $14.3 Bn | 8.6% | 399 |
| 4 | Gastrointestinal Drugs | $4.3 Bn | $7.8 Bn | 6.1% | 2,538 |
| 5 | Asthma & COPD Drugs | $4 Bn | $6.8 Bn | 5.5% | 175 |
| 6 | Biosimilars | $3 Bn | $30.9 Bn | 26.4% | 34 |
| 7 | Cannabis | $2.7 Bn | $11 Bn | 15% | 5 |
| 8 | HIV Drugs | $2.4 Bn | $4.9 Bn | 7.3% | 30 |
| 9 | Contraceptives Drugs | $2 Bn | $4.5 Bn | 8.3% | 0 |
| 10 | Cancer Supportive Care Drugs | $2 Bn | $3.6 Bn | 6.2% | 526 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 26.4% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (24.5%).
Oncology/Cancer Drugs is the largest, worth about $14.2 Bn in 2023 and $36.6 Bn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.